mercredi 30 septembre 2026
RechercherExplore
fr.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue?

View original at finance.yahoo.com
Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue? A month has gone by since the last earnings report for Merck (MRK). Shares have added about 1.7% in that time frame, outperforming the S&P 500…
Opening lines of the source · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Roche Holding has a Zacks Rank #3 (Hold)

    80% confidence

  • Generic competition for Januvia/Janumet, Bridion and Dificid is expected to hurt revenues by approximately $2.5 billion in 2026

    80% confidence

  • In 2026, Merck expects to buy back shares worth $3 billion

    80% confidence

  • Merck has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months

    80% confidence

  • The estimate of $70 billion was $20 billion more than its previous estimate a year ago

    80% confidence

  • The estimate of $70 billion was more than double the peak consensus estimate for Keytruda revenues of $35 billion in 2028

    80% confidence

  • Merck expects over $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s

    80% confidence

  • Keytruda growth was negatively impacted by approximately $200 million due to the unfavorable timing of wholesaler purchases in the United States in Q4 2025

    80% confidence

  • Merck expects revenues to be in the range of $65.5-$67.0 billion in 2026, representing year-over-year growth of 1% to 3%

    80% confidence

  • A lower-than-expected infant immunization rate and high inventory levels in the market hurt Enflonsia sales in Q4 2025

    80% confidence

  • Adjusted earnings per share are expected to be between $5.00 and $5.15 in 2026

    80% confidence

  • The adjusted gross margin is expected to be around 82% in 2026

    80% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
The Agentic Takeover of the CFO's Office
Enterprise finance software vendors—BlackLine, OneStream, Numero AI, and Oracle—are racing to embed autonomous AI agents into core financial operations (close, consolidation, reporting), backed by consolidation M&A (Numero-Royu, BlackLine-WiseLayer), fresh leadership hires, and survey data showing nearly a quarter of CFOs plan to boost AI spending over 50%. Adoption momentum is strong even as at least one bellwether (Oracle) sees its stock lag year-to-date, suggesting the market hasn't yet fully priced in the shift from AI-as-feature to AI-as-agent in finance.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Morgan Stanley & Co. LLC
Two significantly different EPS values (10.21 vs 2.68 USD_per_share) are reported for Morgan Stanley on the same observation date (2025-12-31). Fact A specifies FY 2025, while Fact B's 'N/A' fiscal period is ambiguous. If both represent FY 2025 annual EPS, these values directly conflict. The magnitude of the difference (3.8x) is too large to attribute to rounding or minor calculation variations. The missing fiscal period in Fact B raises data quality concerns, but same-date observation + same attribute should reference the same period.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,984
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,984 faits vérifiés avec la source5,315 documents sources archivés
Interrogez ces données → isubstrate.com
Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue? — Source | Via News | fr.VIA.NEWS